Cargando…

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and hepatic safety. The analysis included 551 antiretrov...

Descripción completa

Detalles Bibliográficos
Autores principales: Maggi, Paolo, Ricci, Elena Delfina, Martinelli, Canio Vito, De Socio, Giuseppe Vittorio, Squillace, Nicola, Molteni, Chiara, Masiello, Addolorata, Orofino, Giancarlo, Menzaghi, Barbara, Bellagamba, Rita, Vichi, Francesca, Celesia, Benedetto Maurizio, Madeddu, Giordano, Pellicanò, Giovanni Francesco, Carleo, Maria Aurora, Cascio, Antonio, Parisini, Andrea, Taramasso, Lucia, Valsecchi, Laura, Calza, Leonardo, Rusconi, Stefano, Sarchi, Eleonora, Martini, Salvatore, Bargiacchi, Olivia, Falasca, Katia, Cenderello, Giovanni, Ferrara, Sergio, Di Biagio, Antonio, Bonfanti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383194/
https://www.ncbi.nlm.nih.gov/pubmed/37515298
http://dx.doi.org/10.3390/v15071612
_version_ 1785080847567683584
author Maggi, Paolo
Ricci, Elena Delfina
Martinelli, Canio Vito
De Socio, Giuseppe Vittorio
Squillace, Nicola
Molteni, Chiara
Masiello, Addolorata
Orofino, Giancarlo
Menzaghi, Barbara
Bellagamba, Rita
Vichi, Francesca
Celesia, Benedetto Maurizio
Madeddu, Giordano
Pellicanò, Giovanni Francesco
Carleo, Maria Aurora
Cascio, Antonio
Parisini, Andrea
Taramasso, Lucia
Valsecchi, Laura
Calza, Leonardo
Rusconi, Stefano
Sarchi, Eleonora
Martini, Salvatore
Bargiacchi, Olivia
Falasca, Katia
Cenderello, Giovanni
Ferrara, Sergio
Di Biagio, Antonio
Bonfanti, Paolo
author_facet Maggi, Paolo
Ricci, Elena Delfina
Martinelli, Canio Vito
De Socio, Giuseppe Vittorio
Squillace, Nicola
Molteni, Chiara
Masiello, Addolorata
Orofino, Giancarlo
Menzaghi, Barbara
Bellagamba, Rita
Vichi, Francesca
Celesia, Benedetto Maurizio
Madeddu, Giordano
Pellicanò, Giovanni Francesco
Carleo, Maria Aurora
Cascio, Antonio
Parisini, Andrea
Taramasso, Lucia
Valsecchi, Laura
Calza, Leonardo
Rusconi, Stefano
Sarchi, Eleonora
Martini, Salvatore
Bargiacchi, Olivia
Falasca, Katia
Cenderello, Giovanni
Ferrara, Sergio
Di Biagio, Antonio
Bonfanti, Paolo
author_sort Maggi, Paolo
collection PubMed
description Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and hepatic safety. The analysis included 551 antiretroviral treatment (ART)-experienced people living with HIV (PLWH), starting RPV-based or DOR-based regimens with viral load < 200 copies/mL, baseline (T0), and at least one control visit (6-month visit, T1). We enrolled 295 PLWH in the RPV and 256 in the DOR cohort. At T1, total cholesterol (TC), low-density lipoprotein-C (LDL-C), and triglycerides significantly decreased in both DOR and RPV cohorts, while high-density lipoprotein-C (HDL-C) only decreased in RPV-treated people. Consistently, the TC/HDL-C ratio declined more markedly in the DOR (−0.36, p < 0.0001) than in the RPV cohort (−0.08, p = 0.25) (comparison p = 0.39). Similar trends were observed when excluding the PLWH on lipid-lowering treatment from the analysis. People with normal alanine aminotransferase (ALT) levels showed a slight ALT increase in both cohorts, and those with baseline ALT > 40 IU/L experienced a significant decline (−14 IU/L, p = 0.008) only in the DOR cohort. Lipid profile improved in both cohorts, and there was a significant reduction in ALT in PLWH with higher-than-normal baseline levels on DOR-based ART.
format Online
Article
Text
id pubmed-10383194
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103831942023-07-30 Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting Maggi, Paolo Ricci, Elena Delfina Martinelli, Canio Vito De Socio, Giuseppe Vittorio Squillace, Nicola Molteni, Chiara Masiello, Addolorata Orofino, Giancarlo Menzaghi, Barbara Bellagamba, Rita Vichi, Francesca Celesia, Benedetto Maurizio Madeddu, Giordano Pellicanò, Giovanni Francesco Carleo, Maria Aurora Cascio, Antonio Parisini, Andrea Taramasso, Lucia Valsecchi, Laura Calza, Leonardo Rusconi, Stefano Sarchi, Eleonora Martini, Salvatore Bargiacchi, Olivia Falasca, Katia Cenderello, Giovanni Ferrara, Sergio Di Biagio, Antonio Bonfanti, Paolo Viruses Article Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and hepatic safety. The analysis included 551 antiretroviral treatment (ART)-experienced people living with HIV (PLWH), starting RPV-based or DOR-based regimens with viral load < 200 copies/mL, baseline (T0), and at least one control visit (6-month visit, T1). We enrolled 295 PLWH in the RPV and 256 in the DOR cohort. At T1, total cholesterol (TC), low-density lipoprotein-C (LDL-C), and triglycerides significantly decreased in both DOR and RPV cohorts, while high-density lipoprotein-C (HDL-C) only decreased in RPV-treated people. Consistently, the TC/HDL-C ratio declined more markedly in the DOR (−0.36, p < 0.0001) than in the RPV cohort (−0.08, p = 0.25) (comparison p = 0.39). Similar trends were observed when excluding the PLWH on lipid-lowering treatment from the analysis. People with normal alanine aminotransferase (ALT) levels showed a slight ALT increase in both cohorts, and those with baseline ALT > 40 IU/L experienced a significant decline (−14 IU/L, p = 0.008) only in the DOR cohort. Lipid profile improved in both cohorts, and there was a significant reduction in ALT in PLWH with higher-than-normal baseline levels on DOR-based ART. MDPI 2023-07-23 /pmc/articles/PMC10383194/ /pubmed/37515298 http://dx.doi.org/10.3390/v15071612 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Maggi, Paolo
Ricci, Elena Delfina
Martinelli, Canio Vito
De Socio, Giuseppe Vittorio
Squillace, Nicola
Molteni, Chiara
Masiello, Addolorata
Orofino, Giancarlo
Menzaghi, Barbara
Bellagamba, Rita
Vichi, Francesca
Celesia, Benedetto Maurizio
Madeddu, Giordano
Pellicanò, Giovanni Francesco
Carleo, Maria Aurora
Cascio, Antonio
Parisini, Andrea
Taramasso, Lucia
Valsecchi, Laura
Calza, Leonardo
Rusconi, Stefano
Sarchi, Eleonora
Martini, Salvatore
Bargiacchi, Olivia
Falasca, Katia
Cenderello, Giovanni
Ferrara, Sergio
Di Biagio, Antonio
Bonfanti, Paolo
Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
title Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
title_full Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
title_fullStr Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
title_full_unstemmed Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
title_short Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
title_sort lipids and transaminase in antiretroviral-treatment-experienced people living with hiv, switching to a doravirine-based vs. a rilpivirine-based regimen: data from a real-life setting
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383194/
https://www.ncbi.nlm.nih.gov/pubmed/37515298
http://dx.doi.org/10.3390/v15071612
work_keys_str_mv AT maggipaolo lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT riccielenadelfina lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT martinellicaniovito lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT desociogiuseppevittorio lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT squillacenicola lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT moltenichiara lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT masielloaddolorata lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT orofinogiancarlo lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT menzaghibarbara lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT bellagambarita lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT vichifrancesca lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT celesiabenedettomaurizio lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT madeddugiordano lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT pellicanogiovannifrancesco lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT carleomariaaurora lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT cascioantonio lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT parisiniandrea lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT taramassolucia lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT valsecchilaura lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT calzaleonardo lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT rusconistefano lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT sarchieleonora lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT martinisalvatore lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT bargiacchiolivia lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT falascakatia lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT cenderellogiovanni lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT ferrarasergio lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT dibiagioantonio lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting
AT bonfantipaolo lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting